Skip to main content
. 2017 Sep 5;6:1643. [Version 1] doi: 10.12688/f1000research.11371.1

Table 2. Serum protein biomarkers for pancreatic cancer, 2012–2017.

Author (year) Biomarker/
Combination
(serum)		 PDAC, number Benign
controls,
number		 Healthy
volunteers,
number		 Sensitivity Specificity Area
under
the
curve
Single biomarkers
Sogawa et al. (2016) 97 C4BPA 52 20 40 67% 95% 0.860
Rychlikova et al. (2016) 98 Osteopontin 64 71 48 - - -
Lin et al. (2016) 99 APOA-I 78 - 36 96% 72.2% 0.880
Lin et al. (2016) 99 TF 78 - 36 75% 72.8% 0.760
Guo et al. (2016) 100 Dysbindin 250 80 150 81.9% 84.7% 0.849
Han et al. (2015) 101 Dickkopf-1 140 - 92 89.3% 79.3% 0.919
Qu et al. (2015) 102 DCLK1 74 74 - - - 0.740
Dong et al. (2015) 103 Survivin 80 - 80 - - -
Gebauer et al. (2014) 104 EpCAM 66 43 104 66.7% 77.5% -
Wang et al. (2014) 105 MIC-1 807 165 500 65.8% 96.4% 0.935
Kendrick et al. (2014) 106 IGFBP2 84 40 84 22% 95% 0.655
Kendrick et al. (2014) 106 MSLN 84 40 84 17% 95% 0.668
Kang et al. (2014) 107 COL6A3 44 46 30 - - 0.975
Willumsen et al. (2013) 108 C1M 15 - 33 - - 0.830
Willumsen et al. (2013) 108 C3M 15 - 33 - - 0.880
Willumsen et al. (2013) 108 C4M 15 - 33 - - 0.940
Willumsen et al. (2013) 108 C4M12a1 15 - 33 - - 0.890
Falco et al. (2013) 109 BAG3 52 - 44 75% 75% 0.770
Falco et al. (2013) 109 BAG3 52 17 (chronic
pancreatitis)		 - 81% 77% 0.810
Chen et al. (2013) 110 TTR 40 - 40 91% 47% 0.730
Gold et al. (2013) 111 PAM4 298 - 79 76% 96% -
Gold et al. (2013) 111 PAM4 298 120 - - - 0.890
Poruk et al. (2013) 112 OPN 86 48 86 - - 0.720
Poruk et al. (2013) 112 TIMP-1 86 48 86 - - 0.770
Lee et al. (2014) 113 CA 19-9 41 12 44 80.4% 70% 0.833
Lee et al. (2014) 113 Human
complement
factor B (CFB)		 41 12 44 73.1% 97.9% 0.958
Mixed cohorts
Ince et al. (2014) 93 CEA 96 (41 PDAC +25 BTC) 129 - 42.7% 89.9% 0.713
Ince et al. (2014) 93 CA19-9 96 (41 PDAC +25 BTC) 129 - 49% 84.5% 0.701
Ince et al. (2014) 93 VEGFR3 96 (41 PDAC +25 BTC) 129 - 48.4% 82.9% 0.622
Ince et al. (2014) 93 Total antioxidant
capacity		 96 (41 PDAC +25 BTC) 129 - 61.1% 60.5% 0.602
Abdel-Razik et al. (2016) 114 IGF-1 47 (25 PDAC + 18 BTC) 62 - 62% 51% 0.605
Abdel-Razik et al. (2016) 114 VEGF 47 (25 PDAC + 18 BTC) 62 - 58.3% 57.3% 0.544
Biomarker combinations
Chen et al. (2013) 110 TTR + CA19-9 40 - 40 81% 85% 0.910
Lee et al. (2014) 113 CA19-9 + CFB 41 12 44 90.1% 97.2% 0.986
Sogawa et al. (2016) 97 C4BPA + CA19-9 52 20 40 86% 80% 0.930
Makawita et al. (2013) 115 CA19-9 + REG1B 100 - 92 - - 0.880
Makawita et al. (2013) 115 CA19-9 + SYCN
+ REG1B		 100 - 92 - - 0.870
Willumsen et al. (2013) 108 C1M + C3M +
C4M + C4M12a1		 15 - 33 - - 0.990
Shaw et al. (2014) 116 IL10 + IL6 +
PDGF + Ca19-9		 84 45 (benign) - 93% 58% 0.840
Shaw et al. (2014) 116 IL8 + IL6 +
IL-10 + Ca19-9		 84 32 (chronic
pancreatitis)		 - 75% 91% 0.880
Shaw et al. (2014) 116 IL8 + IL1b +
Ca 19-9		 127 - 45 94% 100% 0.857
Brand et al. (2011) 117 Ca-19 + CEA +
TIMP-1		 173 70 120 71% 89% -
Capello et al. (2017) 118 TIMP1 + LRG1
+ Ca19-9 		73 - 60 0.849% 0.633% 0.949
Capello et al. (2017) 118 TIMP1 + LRG1
+ Ca19-9		 73 74 - 0.452% 0.541% 0.890
Chan et al. (2014) 119 Ca19-9 + Ca125
+ LAMC2		 139 65 10 82% 74%% 0.870
Makawita et al. (2013) 115 CA19-9 + REG1B 82 41 92 - - 0.875
Makawita et al. (2013) 115 CA19-9 + SYNC
+ REG1B		 82 41 92 - - 0.873
Makawita et al. (2013) 115 CA19-9 + AGR2
+ REG1B		 82 41 92 - - 0.869

BTC, biliary tract cancer; PDAC, pancreatic ductal adenocarcinoma.